RA0779

antibody from Oursmab

Targeting: TNFRSF8 CD30, D1S166E, KI-1

Western blot (Supportive data in Antibodypedia)

ELISA (Supportive data in Antibodypedia)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0779

Provider

Oursmab

Product name

Brentuximab (Biosimilar Reference Antibody) (TNFRSF8)

Antibody type

Monoclonal

Description

Brentuximab vedotin (Adcetris?) is a targeted antibody-drug conjugate (ADC) approved for treating specific CD30-positive lymphomas, primarily classical Hodgkin lymphoma and systemic anaplastic large cell lymphoma. It consists of an anti-CD30 monoclonal antibody linked to the potent cytotoxic agent monomethyl auristatin E (MMAE) via a protease-cleavable linker. The drug binds to CD30 on lymphoma cells, is internalized, and releases MMAE inside the cell, where it disrupts microtubules, arrests the cell cycle, and induces apoptosis. This targeted approach delivers chemotherapy directly to cancer cells while minimizing damage to healthy tissues.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.

Western blot

Supportive validation

Submitted by

Oursmab (provider)

Main image

Experimental details

Brentuximab (Biosimilar Reference Antibody) (TNFRSF8)-RA0779-Oursmab determined by SDS-PAGE. The purity of the protein is greater than 98%.

ELISA

Supportive validation

Submitted by

Oursmab (provider)

Main image

Experimental details

ELISA plate pre-coated Antigen protein, can bind Brentuximab (Biosimilar Reference Antibody) (TNFRSF8)-RA0779 in a linear range of 3.91-125 ng/mL.